OptimizeRx (OPRX) AI Stock Analysis

• Market Cap: $402.49M
• Dividend Yield: N/A
• Average Volume (3M): 309.61K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.05
• Revenue Growth: 25.90%
• EPS Growth: 46.13%
• Country: US
• Employees: 128
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.24
• Shares Outstanding: 18,565,033
• 10 Day Avg. Volume: 247,396
• 30 Day Avg. Volume: 309,605
• PEG Ratio: -0.65
• Price to Book (P/B): 0.76
• Price to Sales (P/S): 0.97
• P/FCF Ratio: 18.61
• Enterprise Value/Market Cap: 0.67
• Enterprise Value/Revenue: 2.57
• Enterprise Value/Gross Profit: 3.99
• Enterprise Value/Ebitda: 258.50
• 1Y Price Target: $22.00
• Price Target Upside: 4.56% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 66 Neutral
• Price Target: $23.50 ▲(11.69% Upside)

OptimizeRx's overall stock score is driven by strong technical analysis and positive earnings call outcomes, highlighting significant revenue growth and improved financial guidance. However, challenges in profitability and valuation due to negative earnings and lack of dividends weigh down the score. The company's solid balance sheet and improving cash flow provide a stable foundation, but operational efficiency needs enhancement.

Positive Factors

Revenue Growth

Substantial revenue growth indicates strong market demand and effective business strategies, positioning OptimizeRx for continued expansion.

Strategic Partnerships

The partnership with Lamar Advertising enhances OptimizeRx's market reach and capability to deliver data-driven advertising, strengthening its competitive position.

Debt Reduction

Significant debt reduction improves financial stability and flexibility, allowing OptimizeRx to invest in growth opportunities and reduce financial risk.

Negative Factors

Profitability Challenges

Ongoing profitability issues could hinder long-term sustainability, as negative margins may limit reinvestment in growth and innovation.

Managed Service Revenue Uncertainty

Uncertainty in managed service revenue could impact future earnings stability, as reliance on unpredictable revenue streams poses a risk to consistent financial performance.

Negative Return on Equity

Negative return on equity indicates inefficiencies in generating returns, which may deter investors and impact the company's ability to raise capital.

OptimizeRx Business Overview & Revenue Model

Company Description

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers, and patients. The company's products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems; and brand awareness and therapeutic support messaging services, such as brand awareness messages, reminder ads, and therapeutic support and unbranded messages. It also offers brand support services, which focuses on educating and working with pharmaceutical manufacturers on identifying, formulating, and implementing eRx media strategies, including drug file integration, sales force training, and strategy development services for promoting their products. In addition, the company operates cloud based Mobile Health Messenger platform that provides interactive health messaging for enhanced medication adherence and care coordination; and HIPAA-compliant automated mobile messaging platform, which allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance. Further, it offers patient programs with treatment and affordability information, lifestyle and condition trackers, internet device connectivity, forms, and surveys. Additionally, the company provides evidence-based physician engagement solution applied to real-world data to assist healthcare providers in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations. It also offers therapy initiation workflow focused on accelerating patient access to treatments where time-consuming medical documentation is required of HCPs prior to pharmacies dispensing prescribed drugs. The company was found in 2006 and is headquartered in Rochester, Michigan.

How the Company Makes Money

OptimizeRx generates revenue primarily through its digital health platform, which offers services to pharmaceutical companies, healthcare providers, and payers. The company earns money by charging pharmaceutical manufacturers for access to its platform, where they can promote their patient support programs and discounts directly to healthcare providers. Additionally, OptimizeRx monetizes its EHR integrations by providing value-added services that enhance the functionality of electronic health records, driving user engagement and adoption. Partnerships with leading EHR vendors and collaborations with various healthcare stakeholders further contribute to its revenue streams by expanding its market reach and enhancing its service offerings.

OptimizeRx Financial Statement Overview

Summary

OptimizeRx shows positive revenue and cash flow growth, but faces profitability challenges with negative net profit margins. The strong equity position and low leverage provide a stable financial foundation.

Income Statement

OptimizeRx shows a positive revenue growth trend, with a TTM revenue increase of 2.43% compared to the previous year. However, the company is facing profitability challenges, as indicated by negative EBIT and net income margins. The gross profit margin remains strong at 62.97%, but the net profit margin is negative at -16.33%, reflecting ongoing operational inefficiencies.

Balance Sheet

The balance sheet reflects a solid equity position with a debt-to-equity ratio of 0.28, indicating low leverage. The equity ratio is robust at 69.28%, showing a strong capital structure. However, the company has experienced a decline in total assets, which may impact future growth potential.

Cash Flow

OptimizeRx demonstrates a positive trend in cash flow, with a significant increase in free cash flow by 32.12% in the TTM period. The operating cash flow to net income ratio is favorable, indicating efficient cash generation relative to net losses. However, the company needs to maintain this momentum to ensure long-term financial stability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	104.75M	92.13M	71.52M	62.45M	61.29M	43.31M
Gross Profit	67.45M	59.38M	42.90M	38.97M	35.64M	24.11M
EBITDA	1.04M	-8.90M	-21.31M	-9.42M	2.33M	646.89K
Net Income	-9.87M	-20.11M	-17.57M	-11.44M	378.08K	-2.21M
Balance Sheet
Total Assets	169.26M	171.17M	183.37M	134.65M	140.99M	60.33M
Cash, Cash Equivalents and Short-Term Investments	16.59M	13.38M	13.85M	74.14M	84.68M	10.52M
Total Debt	3.85M	33.19M	36.82M	234.43K	327.71K	448.75K
Total Liabilities	49.98M	54.17M	56.82M	8.54M	9.61M	10.35M
Stockholders Equity	119.28M	117.00M	126.55M	126.11M	131.38M	49.97M
Cash Flow
Free Cash Flow	10.16M	4.78M	-8.11M	10.41M	240.04K	-6.44M
Operating Cash Flow	10.41M	4.89M	-7.24M	10.65M	726.04K	-6.31M
Investing Cash Flow	-340.00K	-450.00K	-25.34M	-58.18M	-486.00K	-124.72K
Financing Cash Flow	-8.45M	-4.91M	28.22M	-18.95M	73.92M	-1.90M

OptimizeRx Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 21.04
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OPRX, the sentiment is Positive. The current price of 21.04 is above the 20-day moving average (MA) of 19.30, above the 50-day MA of 18.52, and above the 200-day MA of 12.07, indicating a bullish trend. The MACD of 0.69 indicates Negative momentum. The RSI at 59.11 is Neutral, neither overbought nor oversold. The STOCH value of 74.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OPRX.

OptimizeRx Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SPOK	―	$337.90M	19.86	11.03%	7.62%	1.79%	8.48%
HSTM	―	$765.63M	38.82	5.81%	0.47%	3.50%	13.99%
OMCL	―	$1.38B	60.69	1.87%	―	6.39%	―
OPRX	―	$402.49M	―	-8.21%	―	25.90%	46.13%
TBRG	―	$293.03M	-23.13	-6.81%	―	3.42%	77.05%
SOPH	―	$287.21M	-3.87	-74.09%	―	7.31%	-7.49%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

OptimizeRx Corporate Events

OptimizeRx Announces Leadership Changes for Strategic Growth

On August 19, 2025, OptimizeRx Corporation announced leadership changes aimed at accelerating its strategic growth and achieving the Rule of 40 strategy, which balances sustained growth with increased profitability. Brendan Merrell was appointed as the Chief Operating Officer, while Edward Stelmakh transitioned to the role of Chief Financial & Strategic Officer to lead corporate strategy and financial operations. These changes reflect the company’s commitment to aligning talent and structure with its long-term strategic objectives under CEO Steve Silvestro’s management. The leadership advancements, including the promotion of Andy D’Silva to Chief Business Officer, are designed to enhance the company’s focus on profitable growth and shareholder value creation.

The most recent analyst rating on (OPRX) stock is a Hold with a $18.50 price target. To see the full list of analyst forecasts on OptimizeRx stock, see the OPRX Stock Forecast page.

OptimizeRx Earnings Call: Strong Growth and Positive Outlook

The recent earnings call for OptimizeRx Corporation painted a predominantly positive picture, marked by significant revenue growth, improved financial health, and increased guidance for the coming year. While the company expressed confidence in its strategic positioning and operational excellence, there were some concerns about the sustainability of revenue growth due to reliance on managed services and uncertainties in future revenue predictions. Nonetheless, the positive elements of the call notably outweighed the concerns, leaving investors with an optimistic outlook.

OptimizeRx Reports Strong Q2 2025 Financial Growth

OptimizeRx Corporation, a healthcare technology company based in Waltham, Massachusetts, specializes in connecting life sciences brands with healthcare providers and patients through AI-driven tools. The company recently reported a significant financial improvement for the second quarter of 2025, showcasing a 55% increase in revenue to $29.2 million and a 59% rise in gross profit to $18.6 million year-over-year.